Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial - The Lancet

Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial  The Lancet

Comments

Popular posts from this blog

Different types of doctors in South Africa and their salaries 2022 - Briefly

Internal vs. Family Medicine: Who's Who in Primary Care - Avera Health

Your Covid booster side effects shouldn't be as 'intense' this time — here's what to expect - CNBC